Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mixed Results For EMA's Early Pediatric Advice Pilot

This article was originally published in SRA

Executive Summary

The European Medicines Agency has accepted only four of the 15 applications received so far under its early interaction pilot, which offers free scientific advice to drug companies in an effort to stimulate pediatric development1,2.

You may also be interested in...

‘Not What We Expected,’ R&D Industry Says Of ‘Onerous’ EU Paediatric Regulation

The research-based drug industry has not minced its words in describing the problems it has faced from the EU Paediatric Regulation over the past 10 years.

Parallel EMA-FDA Pediatric Advice On The Cards For Companies

The European Medicines Agency is working on plans to supplement its early advice pilot on pediatric development by providing joint advice with the US FDA and, in some cases, by arranging for a three-way dialogue with companies.

EMA Has Work Cut Out Before New Clinical Trial Portal Goes Live

Companies are being encouraged to become “early adopters” of the EU Clinical Trials Information System when it goes live in December 2021.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts